GlassScriptPhysician profile
David A Koeplin
NPI 1205868965
$1,825.41
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2021: $13.07 · 2022: $299 · 2023: $402 · 2024: $402 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $337.41 | 2022-2025 | Aria Radiation Therapy Management Software, Edge, Varian Ethos Treatment Planning |
| Janssen Biotech, INC. | $206.76 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Varian Medical Systems, INC. | $174.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $150.55 | 2023-2025 | |
| Lilly USA, LLC | $119.36 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $117.48 | 2023-2025 | |
| Elekta, INC. | $103.21 | 2019 | |
| Merck Sharp & Dohme LLC | $83.54 | 2022-2025 | Keytruda, Lynparza |
| Seagen INC. | $65.03 | 2022-2023 | Adcetris |
| Boston Scientific Corporation | $56.96 | 2022-2025 | Spaceoar Vue System - 10ml |
| Servier Pharmaceuticals LLC | $42.71 | 2023 | |
| Stemline Therapeutics INC. | $41.29 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $34.39 | 2024-2025 | Ayvakit |
| Recordati_rare_diseases_inc. | $29.55 | 2025 | Sylvant |
| Myriad Genetic Laboratories, INC. | $28.96 | 2021-2025 | Prolaris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $25.20 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $24.69 | 2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $22.83 | 2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $22.18 | 2024 | Enhertu |
| Pharming Healthcare, INC. | $21.71 | 2023 | Ruconest |
| Janssen Scientific Affairs, LLC | $21.06 | 2022 | |
| Corcept Therapeutics | $19.23 | 2024 | Korlym |
| Adc Therapeutics America, INC. | $18.00 | 2024 | |
| Adaptive Biotechnologies Corporation | $15.94 | 2024 | Clonoseq |
| Sobi, INC | $14.43 | 2023 | |
| Genentech USA, INC. | $14.39 | 2024 | Gazyva, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $13.97 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koeplin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.